Emerging Therapy, Unmet Needs and TPP Insights

See Where Innovation Is Heading and Where It Should

Our report provides comprehensive emerging therapy, unmet needs & TPP insights. We analyze pipeline therapies globally and benchmark them against clinical unmet needs, KOL expectations, payer requirements and patient outcomes.

What We Provide:

Pipeline Insight & Competitive Intelligence across preclinical to Phase 3
Mechanisms of Action: Landscape Review, Trial Designs, trial endpoint analysis & Competitive Readiness
Unmet Need Assessment supported by clinical and real-world evidence
Ideal Target Product Profile (TPP) Frameworks
Differentiation Mapping vs. existing & emerging competitors
Risk/Benefit analysis & Go/No-Go Decision Support

How It Helps You:

Our insights support:

Early clinical strategy and development planning
Designing payer-aligned, competitive TPPs
Trial benchmarking and recruitment projections
Probability os success and key driving factors
Strategic differentiation for BD, licensing & investor discussions
Identifying innovation opportunities

What Strategic Answers Clients Will Receive:

Which pipeline therapies show the strongest potential, and how differentiated are they?
What is the competitive readiness of emerging treatments across MoA, efficacy, safety, and trial design?
What are the highest-priority unmet needs from physicians, patients, and payers?
What TPP attributes are essential to securing clinical adoption and payer acceptance?
What is the launch potential and future positioning of key pipeline assets?
Which innovation areas represent the biggest white-space opportunities?

Reports:

April 7, 2026

Market Outlook and Forecast

Neovascular Age-Related Macular Degeneration (nAMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neovascular Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

April 5, 2026

Market Outlook and Forecast

PD-1 and PD-L1 Inhibitors – Market Outlook, Competitive Landscape, Treatment Utilization, and Market Forecast Report – 2026 To 2036

Thelansis’s “PD-1 and PD-L1 Inhibitors Market Outlook, Competitive Landscape, Treatment Utilization, and Market Forecast Report – 2026 To 2036” offers a comprehensive view of competitive positioning, treatment utilization, and revenue potential as these therapies move across multiple lines of therapy and disease indications over the 2026-2036 forecast period across eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 31, 2026

Market Outlook and Forecast

Advanced or Recurrent Endometrial Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Advanced or Recurrent Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Recurrent Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

April 3, 2026

Market Outlook and Forecast

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy Type 2i treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

April 1, 2026

Market Outlook and Forecast

Autosomal Dominant Hypocalcemia Type 1 (ADH1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Dominant Hypocalcemia Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

March 29, 2026

Market Outlook and Forecast

Advanced and Metastatic Biliary Tract Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Advanced and Metastatic Biliary Tract Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Biliary Tract Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Explore Reports

About Us